FY25 FDA Broad Agency Announcement – Q&A Session
FY25 FDA Broad Agency Announcement – Question and Answer Session
Related Articles
Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma
Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.
FDA Grants Priority Review to Durvalumab in MIBC
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of patients with muscle-invasive bladder cancer in this curative-intent…
Considering 3-Year Follow-Up Data of Cilta-Cel in Multiple Myeloma
Samer A. Al’Hadidi, MD, discusses the follow-up data for ciltacabtagene autoleucel in patients with multiple myeloma.
Hot Mulled Cider | Recipes | Cook For Your Life
Hot mulled cider is a real treat to sip, plus it is also a perfect seasonal non-alcoholic drink for holiday parties.
Ohio State to partner with Zangmeister Cancer Center to expand access to cancer care
The OSUCCC – James announces today it will form a new partnership with Zangmeister Cancer Center, a partner practice of American Oncology Network. This
Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors
Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.
Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
BBC – Home
The best of the BBC, with the latest news and sport headlines, weather, TV & radio highlights and much more from across the whole of…
